GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (NAS:LRMR) » Definitions » 3-Year Book Growth Rate

Larimar Therapeutics (Larimar Therapeutics) 3-Year Book Growth Rate : -31.70% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics 3-Year Book Growth Rate?

Larimar Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $1.86.

During the past 12 months, Larimar Therapeutics's average Book Value per Share Growth Rate was -27.40% per year. During the past 3 years, the average Book Value per Share Growth Rate was -31.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of Larimar Therapeutics was -31.70% per year. The lowest was -31.70% per year. And the median was -31.70% per year.

Competitive Comparison of Larimar Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Larimar Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Larimar Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's 3-Year Book Growth Rate falls into.


Larimar Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Larimar Therapeutics  (NAS:LRMR) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Larimar Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics (Larimar Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (NAS:LRMR) » Definitions » 3-Year Book Growth Rate
Comparable Companies
ALT ADAP ABOS GALT RVPH LBPH PDSB ATRA PRAX INMB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ZA71:Germany
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Website
https://www.larimartx.com
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Executives
Gopi Shankar officer: Chief Development Officer C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA 19004
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Russell Clayton officer: Chief Medical Officer 2600 KELLY RD, WARRINGTON PA 18976
Carole Ben-maimon director, officer: President and CEO C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Michael Celano officer: Chief Financial Officer 220 EAST FIRST STREET, BETHLEHEM PA 18015
Joseph Truitt director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Thomas Edward Hamilton director 211 STUYVESANT AVE, RYE NY 10580
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Jonathan S Leff director C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Hif, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Chondrial Therapeutics Holdings, Llc 10 percent owner 150 MONUMENT ROAD, SUITE 207, BALA CYNWYD PA 19004
Deerfield Mgmt Iv, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Healthcare Innovations Fund, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iii, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017